+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Modulation of the Effects of N-Methyl-D,L-Aspartate on Luteinizing Hormone by the Ovarian Steroids in the Adult Rhesus Monkey

      , ,


      S. Karger AG

      N-methyl-D, L-aspartate, Luteinizing hormone, Ovarian steroids, Primate

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Although the excitatory amino acid, N-methyl-DE-aspartate (NMA), is generally thought to stimulate LH release, we have previously reported that NMA inhibits LH secretion in the adult ovariectomized (OVX) rhesus monkey. The objectives of this study were: (1) to compare the effect of NMA on LH in the OVX monkey before and after replacement with ovarian steroids, and (2) to evaluate the LH response to NMA in the intact female monkey during three phases of the menstrual cycle. Three hourly injections of NMA (45 mg i.v.) were given to OVX monkeys (OVX; n = 12) and to OVX animals treated for 4 days with estradiol alone (OVX + E; n = 4) or with estradiol plus progesterone (OVX + E/P; n = 5). Replacement with ovarian steroids prevented the NMA-induced decrease in LH: mean ( ± SE) areas under the LH curve (expressed as a percentage of the 3-hour baseline preinjection control) during the 3-hour NMA treatment period were as follows: OVX,-26.6% ± 2.4; OVX + E, +69.6% ± 33.9; OVX + E/P, + 161.5% ± 59.3 (p < 0.001 vs. OVX). Three hourly NMA (45 mg i.v.) injections were also given to monkeys in the early to mid-follicular phase (n = 5), the late follicular phase (n = 6) and the luteal phase (n = 11). NMA significantly increased LH in the luteal phase: control, 11.5 ± 2.1; peak LH response, 19.8 ± 2.1 (p < 0.005). A small response was observed in the late follicular phase (control, 8.3 ± 0.8; peak LH response, 10.2 ± 1.1; p < 0.05), while no significant response was seen in the early follicular phase. NMA significantly increased cortisol in all groups and no difference was found in regard to the presence or absence of ovarian steroids or to the phase of the menstrual cycle. We conclude that gonadal steroids are required for the excitatory action of NMA on LH secretion in the adult animal. The similar cortisol responses following NMA in all OVX monkeys, whether untreated or replaced with ovarian steroids, and in cyclic animals suggest that activation of the corticotropin-releasing hormone β-endorphin pathway, which in the OVX appears to be responsible for the inhibition of LH, is counteracted in the presence of ovarian steroids.

          Related collections

          Author and article information

          S. Karger AG
          07 April 2008
          : 54
          : 4
          : 405-411
          Center for Reproductive Sciences, Departments of Obstetrics and Gynecology and Physiology, College of Physicians and Surgeons, Columbia University, New York, N.Y., USA
          125921 Neuroendocrinology 1991;54:405–411
          © 1991 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 7
          Original Paper


          Comment on this article